Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).
Pharmaceutical sales were down 3% in the quarter to $3.6 billion, reflecting 7% operational growth and an unfavorable impact from foreign exchange of 10%.
Exchange rate fluctuation affected most results for the quarter. Commercial manufacturing revenues were down 11% to $135.2 million, but gross profit rose by $2.0 million from 2Q08.
Growth in the quarter was driven primarily by 28% growth in revenues for China-based Lab Services to $41.6 million, offset by an 81% decline in manufacturing services revenue.
U.S. revenues were $5.0 billion (-10%) and International revenues were $5.9 billion (-7%). Foreign exchange unfavorably impacted revenues by approximately 5%.
Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact).
Global Specialty Injectables revenue was down 7.5% to 429.7 million, with Europe, Middle East & Africa sales down 26% to $57.6 million and the Americas down 2% to $333.1 million.